GlassScriptPhysician profile
William G Cihak
NPI 1386643781
$4,289.89
in general payments reported to CMS, 2019-2025
36 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $578 · 2021: $714 · 2022: $668 · 2023: $430 · 2024: $515 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $877.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $688.56 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $409.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $278.68 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novo Nordisk INC | $274.14 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $223.05 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $218.38 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.79 | 2019-2025 | Jardiance |
| Abbvie INC. | $145.05 | 2019-2025 | Vraylar |
| Acadia Pharmaceuticals INC | $115.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.76 | 2022-2023 | |
| Amarin Pharma, INC. | $91.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $75.86 | 2019-2023 | |
| Exact Sciences Corporation | $71.64 | 2023-2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65.16 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.63 | 2023-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $32.09 | 2022 | |
| Esperion Therapeutics, INC. | $31.76 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $28.79 | 2024 | Voquezna |
| Allergan, INC. | $27.70 | 2020 | |
| Sumitomo Pharma America, INC. | $25.49 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $24.33 | 2024 | Nuzyra |
| Eisai INC. | $22.84 | 2020 | |
| Dexcom, INC. | $20.75 | 2025 | Dexcom G6 Transmitter |
| Zyla Life Sciences, INC. | $19.56 | 2020 | |
| Astellas Pharma US INC | $17.98 | 2024 | Veozah |
| Almatica Pharma LLC | $16.06 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.57 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $15.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.88 | 2021 | |
| Optinose US, INC. | $14.64 | 2020 | |
| Viatris Specialty LLC | $13.77 | 2025 | Yupelri |
| Valeritas, INC. | $13.15 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.48 | 2019 | |
| Medtronic Minimed, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cihak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.